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Purpose
Anti-IgE antibody had been used in severe persistent
allergic asthma in adults. However, its long-term efficacy
in pediatric patients in India has not been reported.
Method
20 pediatric (12 male and 8 female) patients, with mean
age of 8.5 having severe persistent allergic asthma, with
recurrent exacerbations and on oral/IV steroids, prospec-
tively received Omalizumab 150mg/300mg, depending on
IgE & body weight for 6 month to 1 year,at B.R.Singh
Hospital, Kolkata. Number of exacerbations, total dose of
oral Steroids, use of rescue medications, ICS/LABA dose
used were recorded at the baseline, 24 weeks, end of treat-
ment and on 6 month follow up (between February 2011
and August 2012) and statistically analyzed.
Results
All 20 patients after anti-IgE therapy were followed-up
for 6months.Significant reductions observed in total oral
steroid use by six months -15.5mg (27.5mg vs. 12mg;
95%CI, p<0.001). Use of rescue medications with b2 ago-
nists inhalerdecreased by -7.90 puffs (12.0 vs 4.10 puffs;
95%CI, p-value <0.001) at 24 weeks and by -13.67 puffs
(13.67 vs 0.00 puffs; 95%CI, p-value <0.001) at 52 weeks
(n=6). There was significant reduction in ICS dose at
week 24 by -287.50 mcg (550.0 vs 262.50 mcg; 95%CI,
p-value <0.001). By week 52 (n=6) ICS dose further
declined to -458.33 mcg (750.0 vs 291.67 mcg; 95%CI,
p-value <0.001). 15 (75%) patients had severe asthma
symptoms at baseline,which came down to 6 (30%)
(p<0.05), at week 24. Similarly 15 (75%) patients had
unscheduled hospitalization at baseline, this figure came
down to zero by week 24.
Conclusion
Use of anti-IgE antibody for 6 months to 1 year is well
tolerated and led to overall significant improvement and
stabilization of pediatric patients with severe persistent
allergic asthma which was maintained at 6 months post
treatment follow-up period.
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